News | October 20, 2022
Syngene Q2 FY23 PAT up 11% to Rs. 102 Cr
Revenue from operations up 26% to Rs. 768 crores
Revenue from operations up 26% to Rs. 768 crores
In Q2 FY23, the overall performance of the company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs
For the last ten financial years, the company has posted healthy performance with its revenue from operations growing at 15% CAGR and net profit at 23% CAGR
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
New material distribution will serve medical device and pharmaceutical packaging manufacturers.
_256_384.png)
Amongst the first pharmaceutical companies in India and Asia to be recognised for adopting advanced fourth industrial revolution technologies to digitally transform operations
Dr. Reddy’s largest manufacturing facility in Bachupally, Hyderabad, joins Global Lighthouse Network of the World Economic Forum
Healthcare has become more focused on innovation and technology over the past two years and 80% of healthcare systems are aiming to increase their investment in digital healthcare tools in the coming five years
The MOU provides for assistance in the form of efficient working Capital Management, development and commercialisation of new products, logistic supply chain management support etc.
The ninth acquisition since 2018
Subscribe To Our Newsletter & Stay Updated
